Related Experiment Video
Updated: Oct 25, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Second-Generation Antimitotics in Cancer Clinical Trials.
Pedro Novais1,2,3, Patrícia M A Silva1, Isabel Amorim4
1CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies (IINFACTS), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal.
Second-generation antimitotics targeting the spindle assembly checkpoint (SAC) show promise for cancer therapy. Combination therapies may enhance the efficacy of these microtubule-independent agents, overcoming resistance and toxicity limitations.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Mitosis is a key target for blocking cancer cell proliferation.
- Classical antimitotics (microtubule-targeting agents, MTAs) are effective but face resistance and toxicity.
- Second-generation antimitotics (SGAs) target microtubule-independent pathways, including spindle assembly checkpoint (SAC) components.
Purpose of the Study:
- To provide an updated overview of SGAs that have entered clinical trials.
- To explore future research directions for SGAs, particularly those targeting SAC components.
- To highlight the potential of combination therapies for enhancing SGA efficacy.
Main Methods:
- Review of clinical trial data for SGAs.
- Analysis of preclinical assay outcomes for mitotic and SAC inhibitors.
- Literature review focusing on microtubule-independent antimitotic strategies.
Main Results:
- Many SGAs targeting mitotic and SAC components have shown preclinical promise.
- Most SGAs entering clinical trials demonstrated limited efficacy as monotherapy, failing to progress beyond Phase II.
- Combination therapies are emerging as a strategy to improve SGA effectiveness.
Conclusions:
- SGAs targeting SAC components represent a promising avenue for cancer treatment.
- Overcoming limitations of MTAs requires novel strategies like microtubule-independent inhibition.
- Combination therapies are crucial for realizing the full therapeutic potential of SGAs.
More Related Videos
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Treatment Resistant Cancers
Drugs that Destabilize Microtubules
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...